Summarized by Daily Strand AI from peer-reviewed source
Tuberculosis, the bacterial lung infection that kills more than a million people worldwide each year, has long been treated as a disease you either survive or don't. A major new study published in Nature Medicine challenges that framing, finding that people who are diagnosed with TB and successfully treated still face a significantly elevated risk of dying in the years that follow compared to people who never had the disease. The research drew on data from the 100 Million Brazilian Cohort, one of the largest population-level health datasets ever assembled, giving the findings unusual statistical weight. What makes the results especially striking is that the elevated mortality risk spans multiple organ systems, not just the lungs. TB survivors faced higher rates of death from cancer (oncological causes), heart disease (cardiovascular causes), hormonal and metabolic disorders (endocrine causes), and respiratory conditions long after their infection was cleared.
This research reframes TB as something closer to a chronic condition with lasting consequences rather than an acute illness that ends at the completion of antibiotic treatment. TB remains one of the world's leading infectious disease killers, disproportionately affecting lower-income populations, and Brazil alone records hundreds of thousands of new cases each year. If the damage TB does to the body lingers and raises the risk of dying from cancer, heart disease, or other conditions years later, then current care models that discharge patients after treatment completion may be leaving survivors without the monitoring and follow-up they need. It is worth noting that the abstract does not provide specific numbers for how much greater the risk is, how many years of follow-up were included, or full details on how the researchers accounted for other factors that might influence mortality. The full study would need to be consulted for those critical details, and the findings, while drawn from a very large dataset, reflect the Brazilian population and may not translate uniformly to other settings.
Interested in General Biotech?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.